Divanillyltetrahydrofuran

3,4-Divanillyltetrahydrofuran (Divanil / DVTHF): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Designations

3,4-Divanillyltetrahydrofuran is a lignan found in an Urtica dioica (stinging nettle) subspecies. The compound is also commonly abbreviated as DVTF, DVTHF, or 3,4-D, and is marketed under the trade name Divanil. The CAS number of the compound is 34730-78-4 and its molecular formula is C₂₀H₂₄O₅. Its molecular weight is 344.4 g/mol. In chemical databases, 3,4-Divanillyltetrahydrofuran holds PubChem CID 182210.

Chemical Classification

3,4-Divanillyltetrahydrofuran is classified as a lignan, a type of polyphenolic compound found in many plants. Lignans are known for their antioxidant properties and potential health benefits, including effects on hormone metabolism. More specifically, lignans and neolignans are diphenolic compounds which consist of two propylbenzene (C6–C3) structures derived from the phenylpropanoid pathway. Lignans have been identified in many plants and are known for health benefits including protection against certain cancer types and osteoporosis.

It is described as having a brownish powder appearance. 3,4-Divanillyltetrahydrofuran is typically a solid at room temperature. Its solubility characteristics make it suitable for various extraction and formulation processes. The compound is stable under standard laboratory conditions but may be sensitive to extreme pH or oxidative environments.

Structurally, increasing hydrophobicity in the aliphatic part of the lignans (butane-1,4-diol-butanolide-tetrahydrofuran structures) leads to higher binding affinity. In the aromatic part, a 3-methoxy-4-hydroxy substitution pattern is most effective for binding to SHBG. This structural feature — present in 3,4-divanillyltetrahydrofuran — is central to the compound's pharmacological interest.

Botanical Sources

3,4-Divanillyltetrahydrofuran is a lignan of significant interest in the scientific community, primarily sourced from stinging nettle (Urtica dioica) and flaxseed (Linum usitatissimum). The principal plant part used for extraction is the root. The principal natural source of this compound is the root of the stinging nettle plant, Urtica dioica L. Wikidata records also confirm the compound's presence in pomegranate (Punica granatum L.), based on published lignan determination studies.

Additional sources in the genus Urtica have been documented. Urtica fissa E. Pritz. is an important herb that has been traditionally used as ethnic medicine to treat rheumatism, inflammation, diabetes, and benign prostatic hyperplasia by the Han, Uighur, and other minorities in China, and also as an aphrodisiac in Uighur medicine.

Polar extracts of the stinging nettle (Urtica dioica L.) roots contain the lignans (+)-neoolivil, (-)-secoisolariciresinol, dehydrodiconiferyl alcohol, isolariciresinol, pinoresinol, and 3,4-divanillyltetrahydrofuran. Research into U. dioica phytochemistry has confirmed that research results of nettle roots indicated 18 different phenolic components and 8 different lignan components.

Common Preparations and Commercial Forms

The most common form for 3,4-divanillyltetrahydrofuran in dietary supplement product formulations is a 95% powder. Commercially it is sold both as a standalone standardized extract and as an ingredient within multi-component supplements. Critically, the accuracy of these purity claims has been challenged: companies appear to have misled consumers by marketing their divanil as being 95% pure. ThermoLife International conducted extensive tests, botanical analysis, and chromatograph fingerprints which resulted in a purity of less than 5% 3,4-divanillyltetrahydrofuran. Every known supplier and various products on the market labeled with 95% purity of 3,4-D were tested, and all resulted with less than 5% purity.

The synthesis of 3,4-divanillyltetrahydrofuran can be achieved through various chemical methods. A specific method involves the conversion of secoisolariciresinol, a related lignan. The compounds used in SHBG-binding studies were either isolated from Urtica roots or obtained semisynthetically.

2. Traditional and Historical Use

Stinging Nettle in Ethnomedicine

The direct compound 3,4-divanillyltetrahydrofuran was not identified or isolated in traditional medicine systems; rather, it is one of the bioactive constituents of stinging nettle root (Urtica dioica radix), a plant with a well-documented history of medicinal use. Stinging nettle (Urtica dioica L.) has been used as herbal medicine to treat various ailments since ancient times. Historically, stinging nettle has been revered in traditional medicine across Europe, Asia, and North America for its broad spectrum of health benefits.

The roots, rich in bioactive components including 3,4-divanillyltetrahydrofuran, have been used for centuries to address ailments such as joint discomfort, urinary issues, and, notably, male health concerns. One of the most celebrated historical uses of nettle root and its active compounds has been for supporting prostate health and alleviating symptoms of benign prostatic hyperplasia (BPH). Traditional herbalists recognized its ability to promote healthy urinary flow and enhance overall vitality in men.

In Chinese traditional medicine, related species played a parallel role. Urtica fissa E. Pritz. is an important herb that has been traditionally used as ethnic medicine to treat rheumatism, inflammation, diabetes, and benign prostatic hyperplasia by the Han, Uighur, and other minorities in China, and also as an aphrodisiac in Uighur medicine.

In herbal combinations, 3,4-divanillyltetrahydrofuran-containing extracts have often been paired with saw palmetto, pumpkin seed, and pygeum bark in remedies designed to support male reproductive health and hormonal balance. The plant has a very well-known long history of use and wide historical background as stems, leaves, and roots. It has a long history of use as a food source such as soup or curry, and also used as fiber and a medicinal plant.

Regulatory acknowledgment of the traditional use of nettle root extends to modern European phytomedicine. Stinging nettle root is a well-documented treatment for benign prostatic hyperplasia (BPH) in European phytotherapy. It has been approved as such in Germany and Austria, as outlined in the Commission E monograph. Specifically, Germany's Commission E recommends 4–6 g/day of stinging nettle root (Urtica dioica, U. urens) preparations in the treatment of 'Difficulty in urination in benign prostatic hyperplasia stages 1 and 2.'

3. Key Constituents of Urtica dioica Root and Biosynthesis of 3,4-Divanillyltetrahydrofuran

Lignan Profile of Nettle Root

3,4-Divanillyltetrahydrofuran occurs alongside a suite of other lignans and co-constituents in nettle root. The EMA assessment report on Urtica dioica root provides a detailed phytochemical profile: the root contains lectins at 0.05–0.6% (Urtica dioica agglutinin, UDA), and sterols including 0.2–1% β-sitosterol and 0.032–0.2% β-sitosterol-3-O-β-glucoside, as well as other phytosterols (stigmasterol, campesterol, stigmast-4-en-3-one), phenylpropanes, and ceramides.

Phytosterols, lignans, polysaccharides, and the lectin UDA have been discussed in literature as being among the active principles of nettle root; however, data were not considered sufficient for a conclusive evaluation. The broader phytochemical complexity of U. dioica is extensive: this plant contains a broad range of phytochemicals, such as phenolic compounds, sterols, fatty acids, alkaloids, terpenoids, flavonoids, and lignans, that have been widely reported for pharmacological activities including antiviral, antimicrobial, antihelmintic, anticancer, nephroprotective, hepatoprotective, cardioprotective, antiarthritis, antidiabetic, antioxidant, anti-inflammatory, and antiaging effects.

Biosynthetic Pathway

The biosynthesis of lignans such as 3,4-divanillyltetrahydrofuran in U. dioica proceeds via the phenylpropanoid pathway. A 2019 study published in Molecules specifically investigated lignan composition and biosynthesis in nettle: the relatively high expression of UdPLR1 and UdPLR2 in young internodes, core tissue of bottom internodes, and roots is consistent with the high accumulation of lariciresinol and secoisolariciresinol in these tissues. Lignan quantification showed a high abundance of pinoresinol in roots and pinoresinol diglucosides in young internodes and leaves.

A specific method for synthesizing 3,4-divanillyltetrahydrofuran involves the conversion of secoisolariciresinol, a related lignan. Lignans, a large group of phenylpropanoid dimers, are widely distributed across the plant kingdom. Their primary biological function in planta is supposed to be associated with plant defence, particularly in response to pathogen attack. In addition, lignans have received great interest due to their numerous beneficial effects in mammals, such as antihypertensive, antitumor, hepatoprotective, insecticidal, estrogenic, sedative, and antioxidant activities.

Regarding intestinal metabolism, the main intestinal transformation products of plant lignans in humans, enterodiol and enterolactone, together with enterofuran, were checked for SHBG-binding activity. Notably, the metabolite of (-)-3,4-divanillyltetrahydrofuran (enterofuran) showed higher binding affinity to SHBG than the metabolite of secoisolariciresinol (enterodiol, enterolactone).

4. Mechanisms of Action

4.1 Competitive Inhibition of Sex Hormone-Binding Globulin (SHBG)

The primary mechanism attributed to 3,4-divanillyltetrahydrofuran, and the one most thoroughly characterized in the scientific literature, is its competitive inhibition of sex hormone-binding globulin (SHBG). The compound has been found to occupy binding sites of sex hormone-binding globulin (SHBG), thereby reducing the ability of SHBG to bind additional steroid hormones such as estrogens and androgens, mostly testosterone and estradiol.

The foundational in vitro quantification of this binding was performed by Schöttner, Gansser, and Spiteller and published in Planta Medica in 1997. That study examined a panel of Urtica root lignans against human SHBG: their affinity to human sex hormone-binding globulin (SHBG) was tested in an in vitro assay. The main intestinal transformation products of plant lignans in humans, enterodiol and enterolactone, together with enterofuran, were also checked for their activity. All lignans except (-)-pinoresinol developed a binding affinity to SHBG in the in vitro assay. The affinity of (-)-3,4-divanillyltetrahydrofuran was outstandingly high.

A subsequent 1998 study published in the Journal of Natural Products (Schöttner, Spiteller, and Gansser) quantified the interaction further. The natural lignan (-)-3,4-divanillyltetrahydrofuran, among other lignans, was found to reduce the binding of ³H-labeled 5α-dihydrotestosterone (DHT) to human sex hormone-binding globulin (SHBG). (-)-3,4-Divanillyltetrahydrofuran has the highest binding affinity (Ka = 3.2 ± 1.7 × 10⁶ M^-1) of all lignans investigated so far; the reversibility of its binding and a double reciprocal plot suggest a competitive inhibition of the SHBG–DHT interaction.

The binding of this compound to SHBG is characterized by a relatively low affinity compared to endogenous steroid hormones. The compound has been the subject of pharmacological research due to its high binding affinity for sex hormone-binding globulin (SHBG). By occupying binding sites on SHBG, DVTF can reduce the protein's capacity to bind steroid hormones like testosterone and estradiol, thereby potentially increasing the concentration of bioavailable free testosterone in experimental models.

An important mechanistic observation from the EMA assessment was that phytosterol components are thought to be the least important since their content in nettle root is low. In literature, it was discussed that sex hormone binding globulin (SHBG), aromatase, epidermal growth factor, and prostate steroid membrane receptors seem to be involved in the anti-prostatic effect.

4.2 Modulation of SHBG–Receptor Interaction on Prostate Membranes

Beyond simple competitive displacement of sex steroids, the earlier research of Hryb et al. (1995) demonstrated a related but distinct effect: it has been reported that nettle root contains lignan compounds such as 3,4-divanillyltetrahydrofuran which modulate binding of sex hormone-binding globulin (SHBG) to its receptors on prostate cell membranes. This study suggested that the secondary metabolites, lignans, inhibited the binding between SHBG and its prostate receptor. Lignans would seem to affect the interaction of SHBG with its receptor and thus contribute to the slowing down of certain cellular processes. This mechanism is considered a distinct pathway from direct SHBG occupancy and may have particular relevance to BPH pathophysiology.

4.3 Phytoestrogenic Activity

The lignans influence estrogen metabolism by their antioxidant activity. This influence on estrogen metabolism has led to lignans being functionally classified as phytoestrogens. One of the main lignans is 3,4-divanillyltetrahydrofuran, which can be obtained from stinging nettle roots. This classification reflects the compound's structural and functional similarity to mammalian estrogens and its capacity to interact with estrogen-metabolizing systems.

4.4 Inhibition of Aromatase and 5α-Reductase (Nettle Root Extract Level)

Studies using nettle root extracts (not isolated DVTF) have found additional enzymatic effects. U. dioica roots (methanol extracts) were able to inhibit aromatase (AR) and 5α-reductase (5αRE) in a dose-dependent manner (ED50 of 3.58 and 14.7 mg/mL, respectively). It is not established whether 3,4-divanillyltetrahydrofuran specifically, as an isolated compound, accounts for this activity. The steroidal compounds stigmasterol, stigmast-4-en-3-one, and campesterol can inhibit the prostatic sodium/potassium pump, which might also contribute to nettle's effects in BPH.

5. Scientific Evidence by Area of Use

5.1 SHBG Inhibition and Free Testosterone Availability

Evidence level: In vitro / Preclinical only; no human clinical trials on isolated DVTF.

The direct evidence for 3,4-divanillyltetrahydrofuran increasing free testosterone is limited to in vitro studies. 3,4-Divanillyltetrahydrofuran has promising effects in vitro but lacks clinical trials. Studies have shown that 3,4-divanillyltetrahydrofuran binds to SHBG; however, no studies have been conducted to show that more free testosterone will be available in humans.

There is a single published case report. There is one case report where a 19-year-old male who admitted to taking ActivaTe Xtreme™ (a product containing Divanil) was found to have high serum testosterone and a raised luteinizing hormone. This biochemical pattern clearly shows that the boy did not fail to disclose steroid use due to raised luteinizing hormone, which is suppressed with use of anabolic steroids (i.e., raised testosterone, suppressed luteinizing hormone, and abnormal urine steroid profile). One case report does not constitute clinical proof of efficacy.

A significant portion of the current understanding is based on in vitro and preclinical animal studies. Certain extracts of stinging nettle are used by some bodybuilders in an effort to increase free testosterone, but this practice precedes robust clinical verification.

5.2 Benign Prostatic Hyperplasia (BPH) and Urinary Tract Symptoms

Evidence level: Moderate; clinical evidence exists for nettle root extract (not for isolated DVTF specifically).

Clinical trials have been conducted on Urtica dioica root extracts — complex preparations in which 3,4-divanillyltetrahydrofuran is one of multiple constituents — not on isolated DVTF. The EMA has reviewed the evidence base: the effect of different nettle root preparations on BPH was evaluated in older in vitro and in vivo pharmacological studies. Only a few components of the active principle have been identified, and the mechanism of action is still unclear.

The largest single randomized controlled trial was conducted by Safarinejad (2005). A 6-month, double-blind, placebo-controlled, randomized, partial crossover, comparative trial of Urtica dioica with placebo in 620 patients was conducted. Patients were evaluated using the International Prostate Symptom Score (IPSS), the maximum urinary flow rate (Qmax), postvoid residual urine volume (PVR), serum prostatic-specific antigen (PSA), testosterone levels, and prostate size. This 2005 double-blind, placebo-controlled, randomized trial found significant improvement in IPSS, maximum urinary flow rate, and relief of lower urinary tract symptoms compared with placebo, over 6 months of treatment. These improvements were also maintained after 18 months of treatment.

A combination preparation using saw palmetto (160 mg) and nettle root (120 mg) was evaluated by Lopatkin et al. Patients were randomized to receive a placebo or a fixed dose of 160 mg Sabal fruit extract combined with 120 mg nettle root extract over 24 weeks, followed by another 24-week control period during which all patients received medication. IPSS, urinary flow rates, and residual urine volumes improved significantly in the treatment group, providing evidence of a clinically relevant benefit over a period of 96 weeks.

A systematic review and meta-analysis of five randomized double-blind controlled trials totaling 1,128 patients found that the international prostate symptom score (IPSS) (standardized mean difference = −10.47, 95% CI = −18.12 to −2.82, p = 0.007), the peak urinary flow rate (Qmax) (SMD = 4.37, 95% CI = 1.55 to 7.19, p = 0.002), and prostate volume (SMD = −3.63, 95% CI = −4.67 to −2.57, p < 0.00001) indicated that Urtica dioica was more effective than the placebo or controls.

However, regulatory bodies have applied caution. The American Urology Association's updated guideline for the management of lower urinary tract symptoms attributed to BPH (2021) could not make any positive recommendations about supplements and nutraceuticals, including stinging nettle, due to variable results, methods, and quality of studies. The European Association of Urology's 2022 updated guideline on management of non-neurogenic male lower urinary tract symptoms makes no specific recommendation but references the European Union herbal monograph for the traditional use of U. dioica.

An additional double-blind trial in 100 BPH patients reported by Ghorbanibirgani et al. (2013, Iranian Red Crescent Medical Journal) found that nettle causes anti-inflammatory, anti-tumor, and antiviral effects, modulating the immune system, and relieves the symptoms of BPH due to the compounds it contains such as phytosterols, lignans, and polysaccharides. In the related clinical trial, 287 BPH patients treated with nettle showed significant reduction in IPSS, serum PSA, and prostate size.

5.3 Prostate Cancer (Cell Studies Only)

Evidence level: Preliminary, in vitro cell-line study only; no human evidence.

A 2021 study published in Cancer Biotherapy and Radiopharmaceuticals (Tekin et al.) investigated isolated DVTF in prostate cancer cell lines. The behavior of 3,4-divanillyltetrahydrofuran (DTH) was examined against prostate cancer cells with androgen sensitivity differences [LNCaP (+), PC3 (-)]. DTH was obtained by extraction of Urtica dioica roots. The molecular structure of the isolated compound was confirmed as DTH by liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy analyses. To evaluate the association with androgen sensitivity, DTH was radiolabeled with ¹³¹I, and a cell uptake assay was performed. A cytotoxicity (WST-1) assay of DTH was performed against LNCaP and PC3 cells. The results showed that DTH lignan behaves differently by being more toxic to LNCaP cells than PC3 cells, depending on androgen sensitivity. These findings are cell-culture observations only and have no established clinical relevance to prostate cancer treatment or prevention in humans.

5.4 Multi-Ingredient Supplement: Body Composition and Hormonal Profiles in Athletes

Evidence level: Preliminary; small single study on a multi-ingredient product containing DVTF. Cannot isolate DVTF's contribution.

A study published in PLOS ONE (2018) examined a multi-ingredient performance supplement (MIPS) that contained DVTF as one of several herbal ingredients. This study investigated the effects of a MIPS on body composition and hormone levels in college athletes following a six-week training protocol. Twenty male college athletes were equally assigned to MIPS and placebo groups for supplementation (three pills, twice daily) in conjunction with resistance training and specialized sports training (nine total sessions/week) for six weeks. Serum samples collected at weeks 0 and 6 determined free testosterone, total testosterone, IGF-1, and total estrogen levels. The placebo group experienced a significant decline in lean body mass (−1.5 kg; p < 0.05) whereas the MIPS sustained LBM. The MIPS increased total testosterone 21.9% and increased free testosterone 15.2% (p < 0.05). Because the supplement contained multiple ingredients, these results cannot be attributed specifically to 3,4-divanillyltetrahydrofuran.

5.5 Hypogonadism in Diabetes (Animal Model)

Evidence level: Preclinical animal study only; no human evidence.

To determine the effect and potential mechanism of 3,4-divanillyltetrahydrofuran (DVTF), one of the main active components isolated from U. fissa, on hypogonadism in diabetic mice, the active compound DVTF was extracted and separated from the roots of U. fissa. In the pre-experiment, DVTF had no toxicity to mice at the appropriate doses.

5.6 Pharmacokinetics (Preclinical)

Evidence level: Single preclinical study in rats; no human pharmacokinetic data available.

The pharmacokinetic study of 3,4-divanillyltetrahydrofuran is reported for the first time in that 2015 study. 3,4-Divanillyltetrahydrofuran is described as the main active ingredient of nettle root which can increase steroid hormones in the bloodstream. To better understand its pharmacological activities, it was necessary to determine its pharmacokinetic profiles. A rapid and sensitive ultra-fast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) method was developed for the determination of 3,4-divanillyltetrahydrofuran in the plasma of rats. Chromatographic separation was performed on a C18 column at 40°C with a gradient elution consisting of methanol and water containing 0.3% (v/v) formic acid. The detection was performed using an electrospray triple-quadrupole MS/MS via positive ion multiple reaction monitoring mode. A pharmacokinetic study in rats utilizing ultra-fast liquid chromatography/tandem mass spectrometry (UFLC-MS/MS) established a method for its quantitative analysis in plasma, demonstrating its detectable presence and providing a basis for further preclinical investigation. No human pharmacokinetic data on isolated 3,4-divanillyltetrahydrofuran have been published to date.

6. Body Systems and Health Areas of Association

• Endocrine / Hormonal System: 3,4-Divanillyltetrahydrofuran is a lignan that may affect the production of certain hormones in the body involved in the development of secondary sex characteristics. Its documented interaction with SHBG places it within the hormonal regulation domain.
• Male Urogenital / Prostate Health: Several double-blind clinical trials confirmed the efficacy of U. dioica root for relieving the symptoms of benign prostatic hyperplasia (BPH). Nettle root contains lignan compounds such as 3,4-divanillyltetrahydrofuran which modulate binding of sex hormone-binding globulin (SHBG) to its receptors on prostate cell membranes.
• Musculoskeletal / Sports Performance: In recent years, divanillyltetrahydrofuran has gained attention in the sports nutrition and bodybuilding communities as an ingredient in supplements marketed to support healthy testosterone levels and muscle performance.
• Anti-inflammatory: Lignans such as DVTF have received interest for their numerous beneficial effects in mammals including antihypertensive, antitumor, hepatoprotective, estrogenic, sedative, and antioxidant activities. Evidence for anti-inflammatory activity in the context of isolated DVTF is, however, primarily preclinical.
• Oncology (Experimental): Based on cell-line data only, DVTF has been studied for potential associations with androgen-sensitive prostate cancer cells, as described above (Tekin et al., 2021).

7. Dosage Forms and Reported Dosages

No established clinical dosage for isolated 3,4-divanillyltetrahydrofuran exists based on controlled human trials. Reported dosages derive from manufacturer recommendations and from nettle root extract clinical trials where DVTF content is one constituent among several.

• Manufacturers typically recommend doses between 600 mg to 1,500 mg per day.
• Clinical trials for BPH have used aqueous extracts of U. dioica root in dosages of 360 mg daily over 6 months and methanol root extract in dosages of 600 to 1,200 mg daily for 6 to 9 weeks.
• The Safarinejad 2005 crossover trial used 120 mg aqueous extract of U. dioica root three times daily for 6 months in symptomatic BPH subjects aged 55–72.
• The Lopatkin et al. combination study used a fixed dose of 160 mg Sabal fruit extract combined with 120 mg nettle root extract over 24 weeks.
• In the preclinical pharmacokinetic animal study, 25, 50, and 100 mg/kg of DVTF were selected as the low, medium, and high doses by gavage in mice, respectively.
• The German Commission E recommends 4–6 g/day of stinging nettle root preparations in the treatment of difficulty in urination in BPH stages 1 and 2. This refers to dried root equivalent, not an isolated lignan fraction.

8. Safety Considerations and Interactions

Safety Profile of Nettle Root Extracts

Systematic reviews on nettle root as a whole herb provide the most reliable safety data. There are a total of 699 adverse events documented for stinging nettle root across studies; however, the numbers may be higher because many studies did not report adverse events. The most common adverse effects are impotence and decreased libido. The majority of studies were conducted with a 20% methanolic extract. They indicate that this extract has a good short-term safety profile. Trials with longer treatment periods are needed to establish long-term safety; however, short-term treatment is safe and associated with low toxicity levels.

Regarding the isolated compound in animal studies, in pre-experiment work, DVTF had no toxicity to mice at the appropriate doses. No published human toxicological studies on isolated 3,4-divanillyltetrahydrofuran exist.

Purity and Adulteration Concern

A documented safety and efficacy concern specific to DVTF products is the systematic mislabeling of purity. Companies appear to have misled consumers by marketing their divanil as being 95% pure. ThermoLife International conducted extensive tests, botanical analysis, and chromatograph fingerprints which resulted in a purity of less than 5% 3,4-divanillyltetrahydrofuran. Every known supplier and various products on the market labeled with 95% purity were tested, and all resulted with less than 5% purity. This finding means that actual clinical effects observed with labeled "95% Divanil" products may not be attributable to DVTF itself, but to the remaining constituents of the nettle root extract.

Regulatory Status

If used in high-purity form, it would theoretically require a New Dietary Ingredient (NDI) notification submission to the FDA. In Europe, 3,4-divanillyltetrahydrofuran is also not listed among the EFSA-approved food ingredients. If companies intend to use this compound in food supplements, it would generally need to go through the EU's Novel Food approval process. As a specifically extracted and converted lignan compound, it has not yet gained widespread approval in the European market and is therefore regarded as an unapproved novel food ingredient. In Canada, Health Canada maintains strict classification and approval procedures for plant-based ingredients in dietary supplements. 3,4-Divanillyltetrahydrofuran is not listed in the Natural Health Products Ingredients Database (NHPID). This means the compound cannot be sold as an active ingredient in natural health products unless sufficient safety and efficacy data are submitted and approved.

By contrast, Urtica dioica root extract (of which DVTF is a constituent) has traditional use recognition in Germany and Austria under the Commission E, and is referenced in EMA traditional herbal medicinal product monographs for BPH symptom relief.

Theoretical Drug Interactions

No published pharmacological drug-interaction studies specific to isolated 3,4-divanillyltetrahydrofuran exist. Based on its mechanism of action — competitive SHBG displacement, potential modulation of aromatase and 5α-reductase via nettle root extract — theoretical interactions may be anticipated with:

• Exogenous sex hormones or hormonal therapies (testosterone replacement therapy, estrogen therapy), due to displacement from SHBG and potential alteration of free hormone fractions.
• 5α-reductase inhibitors (finasteride, dutasteride) used in BPH treatment, given potential overlapping enzymatic targets at the extract level: combining Urtica dioica root extract with saw palmetto extract may produce clinical benefit equal to that of finasteride.

These interaction possibilities are speculative extrapolations from mechanism and combination studies involving whole nettle root extract, not from pharmacokinetic studies of isolated DVTF.

Estrogenic Concerns

Lignans influence estrogen metabolism by their antioxidant activity; this influence on estrogen metabolism leads to their classification as phytoestrogens. The theoretical consequence of increased free testosterone (via SHBG displacement) includes potential downstream aromatization to estradiol. This has been noted informally in the supplement literature but has not been studied clinically in the context of isolated DVTF.

9. Current State of the Evidence: Summary Assessment

3,4-Divanillyltetrahydrofuran is a well-characterized plant lignan at the chemical level, with established in vitro binding data against human SHBG. 3,4-Divanillyltetrahydrofuran has promising effects in vitro but lacks clinical trials. The compound's parent plant — Urtica dioica root — has a moderately supported clinical evidence base for BPH-related urinary symptom relief, but the contribution of DVTF specifically versus other root constituents (phytosterols, lectins, polysaccharides) to these clinical effects has not been isolated or quantified in controlled human studies.

Only a few components of the active principle have been identified, and the mechanism of action is still unclear. The EMA assessment further notes that overall, clinical studies are not appropriate for traditional use in several indications. Only well-established use can be relevant in these indications; however, they are hardly good enough, and the results of these trials cannot be used. Since a small number of participants were included in the studies and most were not double-blind, and data are not detailed enough, the consequences are not influential.

The commercial supplement landscape for isolated DVTF is complicated by documented widespread mislabeling of purity, making the interpretation of any real-world observations difficult. No human pharmacokinetic, dose-finding, or efficacy studies have been published specifically on the isolated compound, and no safety studies for human use exist in the peer-reviewed literature. Research into the compound remains in the preclinical and in vitro stage as of the current literature.

References

• Schöttner M, Gansser D, Spiteller G. Lignans from the roots of Urtica dioica and their metabolites bind to human sex hormone binding globulin (SHBG). Planta Med. 1997;63(6):529-532. PubMed PMID: 9434605
• Schöttner M, Spiteller G, Gansser D. Lignans interfering with 5α-dihydrotestosterone binding to human sex hormone-binding globulin. J Nat Prod. 1998;61(1):119-121. PubMed PMID: 9461660
• Tekin V, Kozgus Guldu O, Medine EI, Biber Muftuler FZ. Examination of the Association Between 3,4-Divanillyltetrahydrofuran Lignan (Urtica dioica Origin) and Prostate Cancer Cells by ¹³¹I Radiolabeling. Cancer Biother Radiopharm. 2021. PubMed PMID: 32453606
• Study on pharmacokinetics of 3,4-divanillyltetrahydrofuran in rats by ultra-fast liquid chromatography/tandem mass spectrometry. J Chromatogr B. 2015. PubMed PMID: 26680326
• Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005;5(4):1-11. PubMed PMID: 16635963
• Smith SJ, et al. The Effects of a Multi-Ingredient Performance Supplement on Hormonal Profiles and Body Composition in Male College Athletes. PLOS ONE. 2018. PMC5968923
• Insights into Lignan Composition and Biosynthesis in Stinging Nettle (Urtica dioica L.). Molecules. 2019;24(21):3863. PMC6864805
• Urtica dioica-Derived Phytochemicals for Pharmacological and Therapeutic Applications. PMC8894011
• Antinociceptive and anti-inflammatory effects of Urtica dioica leaf extract in animal models. Avicenna J Phytomed. 2014. PMC4075706
• The Efficacy of Stinging Nettle (Urtica Dioica) in Patients with Benign Prostatic Hyperplasia: A Randomized Double-Blind Study in 100 Patients. Iran Red Crescent Med J. 2013. PMC3589769
• PubChem CID 182210: 3,4-Divanillyltetrahydrofuran. National Library of Medicine / PubChem
• Wikipedia: 3,4-Divanillyltetrahydrofuran
• European Medicines Agency (EMA). Final Assessment Report on Urtica dioica L.; Urtica urens L., radix (Revision 1)
• NCCIH. Benign Prostatic Hyperplasia and Complementary and Integrative Approaches: What the Science Says
• Drugs.com Natural Products: Nettles Uses, Benefits & Dosage (medically reviewed)
• HerbalGram / American Botanical Council. Review of Stinging Nettle Root Extract Efficacy for BPH
• Semantic Scholar: Schöttner et al. 1997, Lignans from the roots of Urtica dioica and their metabolites bind to SHBG. Planta Medica.
• ScienceDirect: Study on pharmacokinetics of 3,4-divanillyltetrahydrofuran in rats by UFLC/MS/MS. J Chromatogr B. 2015
• Nutrient Journal: 3,4-Divanillyltetrahydrofuran increases free testosterone (in vitro)
• Wild Stinging Nettle (Urtica dioica L.) Leaves and Roots Chemical Composition and Phenols Extraction. PMC9864842